1. Home
  2. SGRY vs IOVA Comparison

SGRY vs IOVA Comparison

Compare SGRY & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Surgery Partners Inc.

SGRY

Surgery Partners Inc.

N/A

Current Price

$13.23

Market Cap

1.6B

Sector

Health Care

ML Signal

N/A

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

N/A

Current Price

$14.23

Market Cap

1.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SGRY
IOVA
Founded
2004
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Hospital/Nursing Management
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.7B
IPO Year
2015
2008

Fundamental Metrics

Financial Performance
Metric
SGRY
IOVA
Price
$13.23
$14.23
Analyst Decision
Buy
Buy
Analyst Count
12
10
Target Price
★ $18.82
$10.70
AVG Volume (30 Days)
2.1M
★ 12.3M
Earning Date
11-09-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 54.14
14.84
EPS
N/A
★ N/A
Revenue
★ $1,145,438,000.00
N/A
Revenue This Year
N/A
$54.93
Revenue Next Year
N/A
$40.91
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.41
$1.76
52 Week High
$23.44
$15.06

Technical Indicators

Market Signals
Indicator
SGRY
IOVA
Relative Strength Index (RSI) 46.73 86.63
Support Level $13.26 $3.57
Resistance Level $15.02 N/A
Average True Range (ATR) 0.78 0.65
MACD 0.03 0.45
Stochastic Oscillator 32.02 95.63

Price Performance

Historical Comparison
SGRY
IOVA

About SGRY Surgery Partners Inc.

Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities, which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earn revenues from contracts with patients in which the performance obligations are to provide health care services.

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

Share on Social Networks: